A new drug candidate outperforms a standard treatment in heart failure patients, researchers report August 30 in the New England Journal of Medicine. Those receiving the experimental drug called LCZ696 were less likely to die during the study than those getting a common blood pressure–lowering drug.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.